RVMD - Revolution Medicines, Inc.

98.4
-1.240   -1.260%

Share volume: 1,594,795
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$99.64
-1.24
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
14%
Profitability 0%
Dept financing 15%
Liquidity 43%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.17%
1 Month
1.72%
3 Months
22.91%
6 Months
139.65%
1 Year
150.96%
2 Year
212.08%
Key data
Stock price
$98.40
P/E Ratio 
0.00
DAY RANGE
$97.31 - $100.08
EPS 
-$5.77
52 WEEK RANGE
$29.17 - $124.49
52 WEEK CHANGE
$167.25
MARKET CAP 
15.398 B
YIELD 
N/A
SHARES OUTSTANDING 
198.173 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,043,055
AVERAGE 30 VOLUME 
$2,245,420
Company detail
CEO: Mark A. Goldsmith
Region: US
Website: revmed.com
Employees: 250
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Revolution Medicines, Inc. focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trials for solid tumors, such as gynecologic and colorectal cancer tumors.

Recent news